Publications by authors named "Xiang-Qing Yu"

Claim this Profile
A
A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors.
Lillian L Siu, David S Hong, Wolf-Dietrich Döcke, Reimo Tetzner, Mark Trautwein, Xiang Qing Yu

Target Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of anti-alpha toxin antibody levels and colonisation status after administration of an investigational human monoclonal antibody, MEDI4893, against alpha toxin.
Alexey Ruzin, Yuling Wu, Li Yu, Xiang-Qing Yu, David E Tabor

Clin Transl Immunology· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.
Binyam Bezabeh, Ryan Fleming, Christine Fazenbaker, Haihong Zhong, Karen Coffman, Xiang-Qing Yu

MAbs· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.
Mary Jane Masson Hinrichs, Pauline M Ryan, Bo Zheng, Shameen Afif-Rider, Xiang Qing Yu

Clin Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation and Characterization of an IgG4 Monomeric Fc Platform.
Lu Shan, Magali Colazet, Kim L Rosenthal, Xiang-Qing Yu, Jared S Bee

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of antibody functions through Fc multiplications.
Qun Wang, Yan Chen, Mark Pelletier, Romana Cvitkovic, Jessica Bonnell, Xiang-Qing Yu

MAbs· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults.
Xiang-Qing Yu, Gabriel J Robbie, Yuling Wu, Mark T Esser, Kathryn Jensen

Antimicrob Agents Chemother· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical Role of Alpha-Toxin and Protective Effects of Its Neutralization by a Human Antibody in Acute Bacterial Skin and Skin Structure Infections.
Vien T M Le, Christine Tkaczyk, Sally Chau, Renee L Rao, Etyene Castro Dip, Xiang Qing Yu

Antimicrob Agents Chemother· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
Pamela Thompson, Ryan Fleming, Binyam Bezabeh, Fengying Huang, Shenlan Mao, Xiang-Qing Yu

J Control Release· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
Bo Zheng, Xiang-Qing Yu, Warren Greth, Gabriel J Robbie

Br J Clin Pharmacol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving target cell specificity using a novel monovalent bispecific IgG design.
Yariv Mazor, Vaheh Oganesyan, Chunning Yang, Anna Hansen, Jihong Wang, Xiang-Qing Yu

MAbs· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.
M Jack Borrok, Yanli Wu, Nurten Beyaz, Xiang-Qing Yu, Vaheh Oganesyan

J Biol Chem· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa.
Antonio DiGiandomenico, Ashley E Keller, Cuihua Gao, Godfrey J Rainey, Paul Warrener, Xiang-Qing Yu

Sci Transl Med· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors.
Paul Haluska, Michael Menefee, Elizabeth R Plimack, Jonathan Rosenberg, Donald Northfelt, Xiang-Qing Yu

Clin Cancer Res· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
William V La Via, Gerard F Notario, Xiang-Qing Yu, Shringi Sharma, Peter A Noertersheuser

Pulm Pharmacol Ther· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development.
Xiang-Qing Yu, Alan G E Wilson

Future Med Chem· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early toxicology signal generation in the mouse.
Jeffrey A Kramer, Emily O'Neill, Megan E Phillips, Debra Bruce, Traci Smith, Xiang-Qing Yu

Toxicol Pathol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors.
Haihong Jin, Giovanni Cianchetta, Arokiasamy Devasagayaraj, Kunjian Gu, Brett Marinelli, Xiang-Qing Yu, Qingyun Liu

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK.
N Andrew Whitlock, Bryce Harrison, Travis Mixon, Xiang-Qing Yu, Alan Wilson

J Ocul Pharmacol Ther· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro cytotoxicity, in vivo biodistribution and antitumor activity of HPMA copolymer-5-fluorouracil conjugates.
Fang Yuan, Xuan Qin, Dan Zhou, Qing-Yu Xiang, Min-Ting Wang, Yuan Huang

Eur J Pharm Biopharm· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders.
Zhi-Cai Shi, Arokiasamy Devasagayaraj, Kunjian Gu, Haihong Jin, Brett Marinelli, Xiang-Qing Yu, Qingyun Liu

J Med Chem· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract.
Qingyun Liu, Qi Yang, Weimei Sun, Pete Vogel, William Heydorn, Xiang-Qing Yu, Wangsheng Yu

J Pharmacol Exp Ther· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles.
Qing-yu Xiang, Min-ting Wang, Fu Chen, Tao Gong, Yan-lin Jian, Yuan Huang

Arch Pharm Res· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate.
Vincent J Wacher, Jeffrey A Silverman, Susan Wong, Paulina Tran-Tau, Amy O Chan, Xiang-Qing Yu

J Pharmacol Exp Ther· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis